Physician profile
Glen P Imlay
NPI 1053364828
$983.98
in general payments reported to CMS, 2019-2025
22 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $57.85 · 2023: $108 · 2024: $188 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $125.55 | 2019 | |
| Pfizer INC. | $123.63 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.68 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.06 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Bioventus LLC | $106.48 | 2019-2025 | Gelsyn-3, Durolane |
| Astrazeneca Pharmaceuticals LP | $61.39 | 2020-2025 | Breztri, Airsupra |
| Mylan Specialty L.P. | $47.02 | 2019-2023 | Yupelri |
| Lilly USA, LLC | $44.08 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $29.95 | 2019 | |
| Tonix Medicines, INC. | $25.24 | 2025 | Tonmya |
| Paratek Pharmaceuticals, INC. | $23.57 | 2023 | Nuzyra |
| Mdd US Operations, LLC | $18.63 | 2019 | |
| Pacira Therapeutics, INC. | $16.76 | 2019 | |
| Amgen INC. | $16.25 | 2019 | |
| Dexcom, INC. | $15.81 | 2023 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.65 | 2019 | |
| Amarin Pharma, INC. | $14.37 | 2019 | |
| Abbvie INC. | $13.51 | 2023 | |
| Biodelivery Sciences International, INC. | $13.24 | 2019 | |
| Fidia Pharma USA INC. | $12.50 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2019 | |
| Axsome Therapeutics, INC. | $11.14 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Imlay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.